This 2016 case-control study evaluated the diagnostic performance of apolipoprotein A-1 (Apo A-1) compared to high-density lipoprotein (HDL) in detecting coronary artery disease (CAD). The study involved 100 angiographically confirmed CAD patients and 100 age- and sex-matched healthy controls. Results showed significantly lower mean Apo A-1 levels in CAD patients
This 2012 review by Dr. Mark Houston explores the clinical utility of nutraceutical supplements in the management of dyslipidemia. The paper emphasizes a functional medicine approach combining diet with evidence-based nutraceuticals to reduce LDL cholesterol, LDL particle number, VLDL, and triglycerides, while increasing HDL (especially HDL2b) and LDL particle size.
This 2015 clinical study investigated the effects of daily high-dose vitamin C (1250 mg) supplementation over 8 weeks in 46 healthy young adults (including smokers). Results showed enhanced serum antioxidant activity, reduced advanced glycation end products and reactive oxygen species, and improved lipoprotein profiles. Specifically, apoB-48 in LDL disappeared, and
This in vitro and human study investigated the acute effects of intravenous infusion of ApoA-I/phosphatidylcholine (apoA-I/PC) discs on plasma lipoprotein levels in healthy adults. The infusion led to a rapid 60% increase in high-density lipoprotein (HDL) levels within 4 hours (p
This randomized controlled trial examined the effects of intravenously administered apolipoprotein A-I/phosphatidylcholine (apoA-I/PC) discs on key enzymes involved in lipid metabolism and reverse cholesterol transport in human subjects. The infusion significantly increased pre-beta-HDL concentrations in plasma, enhanced lecithin:cholesterol acyltransferase (LCAT) activity to facilitate HDL maturation, and elevated phospholipid transfer protein
